Pharmaceutical Contract Manufacturing Market 2018-2028 - Visiongain Report

Friday, July 13, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

LONDON, July 13, 2018 /PRNewswire/ --

Active Ingredient (API) and Finished Dose Formulation

(FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages

The pharmaceutical contract manufacturing market is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The API Manufacturing submarket held 66% of the market

in 2017. Visiongain estimated that the pharmaceutical contract manufacturing market will reach $93bn in 2022.

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 230-page report you will receive 77 tables and 58 figures- all unavailable elsewhere.

The 230-page report provides clear detailed insight into the pharmaceutical contract manufacturing market. Discover the key drivers and challenges affecting the market. By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope 

• Global Pharmaceutical Contract Manufacturing Market forecasts from 2018-2028

• Submarket forecasts at world level, from 2018-2028: • Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products • Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types • Other applications of outsourced production - other related services

• Revenue forecasts from 2018-2028, for these regional and national markets: • The US Canada Japan • EU5: Germany, France, the UK, Italy and Spain • BRIC: Brazil, Russia, India, China South Korea Turkey Mexico • Others

• Assessment of selected leading companies that hold major market shares in the pharmaceutical contract manufacturing industry

• Qualitative Analysis from a CMO Perspective 

• Qualitative Analysis from a Client Perspective 

Visiongain's study is intended for anyone requiring commercial analyses for the pharmaceutical contract manufacturing market. You find data, trends and predictions.

Buy our report today Pharmaceutical Contract Manufacturing Market 2018-2028: Active Ingredient (API) and Finished Dose Formulation (FDF), Generic APIs, HPAPIs, Solid Dosages, Injectable Dosages.

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website : https://www.visiongain.com/report/pharmaceutical-contract-manufacturing-market-2018-2028

AbbVie Actavis ADC Biotechnology Aegerion Pharmaceuticals Aenova Group Aesica Pharma Agensys Agila Specialties Ajinomoto Althea Inc Alexion Pharmaceuticals Almac Group Althea Technologies AMRI (Albany Molecular Research Inc) API Corporation (APIC) Aspen Pharmacare Astellas AstraZeneca Banner Life Sciences Banner Pharmacaps Baring Private Equity Asia Bausch & Lomb Bayer Healthcare Ben Venue Laboratories Bend Research Biogen Idec BioIndustry Association (BIA) Biotest Blackstone Group Boehringer Ingelheim Boehringer Ingelheim BioXcellence Bristol-Myers Squibb Company Bushu Pharmaceuticals Cambrex Cambridge Major Laboratories Catalent Pharma Solutions Cedarburg Hauser Cell Therapy Catapult Celldex Therapeutics Celltrion Cenexi Chemisch-Pharmazeutisches Laboratorium Ravensburg Chemtrix China FDA (CFDA) Cipla Cook Pharmica CordenPharma CTC Bio Daito Pharmaceutical Delpharm Dishman Pharmaceuticals DPx Fine Chemicals DPx Holdings B.V. Dr. Reddy's Laboratories DSP (DSM Sinochem Pharmaceuticals) Eisai Eli Lilly Esteve Quimica Euticals Evonik Degussa Famar Fareva FUJIFILM Diosynth Biotechnologies, Gallus Biopharmaceutical, LLC. G-CON GEA Pharma-Systems Genentech GlaxoSmithKline (GSK) Granules India Haupt Pharma Hexal Hospira Hospira One2One ImmunoGen Immunomedics Indian Pharmaceutical Alliance Innovent Biologics IRIX Pharmaceuticals Janssen JK Pharmaceutical Johnson & Johnson Knowledge Transfer Network (KTN) Lonza Lupin Marinopoulos Group Matrix Laboratories Medice Medichem Merck & Co. Micron Technologies Millennium Mitsui & Co Momenta Pharmaceuticals Mylan Neuland Laboratories NICE Insight NPS Pharmaceuticals Nycomed Orchid Chemicals & Pharmaceuticals Oxford Biomedica Patheon Patheon Biologics Pfizer Pharmapak Technologies Piramal Pharma Solutions Progenics Quintiles Recepta Biopharma Recipharm Redwood Bioscience Rentschler Biotechnologie Roche Royal DSM SAFC SafeBridge Samsung Bioepis Samsung BioLogics Sandoz Sanofi Seattle Genetics Shandong Xinhua ShangPharma Shire Siegfried AG Sigmar Italia SMS Pharmaceuticals Solvias AG Speedel Stada Stem CentRx Stevenage Bioscience Catalyst Takeda Temmler Group Teva API Thermo Fisher Scientific UMN Pharma UNIGEN Valeant Pharmaceuticals Valerion Therapeutics, LLC. Vetter Pharma-Fertigung GmbH Vivante GMP Solutions West Pharmaceutical Services WuXi PharmaTech Zhangjiang Biotech & Pharmaceutical Base Company Zhejiang Jiang Yuan Tang Biotechnology

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store